Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Major Depressive Disorder
Interventions: XEN1101 10 mg, XEN1101 20 mg, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 20
States / cities: Anaheim, California • Lafayette, California • Pico Rivera, California + 15 more

Conditions: Pulmonary Disease, Chronic Obstructive, Major Depression
Interventions: Treatment Adherence Intervention, Enhanced Care; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: West Haverstraw, New York • White Plains, New York

Conditions: Major Depressive Disorder
Interventions: Mindset: Therapist-guided smartphone-delivered CBT; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: motivational interviewing, brief advice in primary care; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 14 Years to 75 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Disorder
Interventions: Saredutant succinate (SR48968C); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Depression
Interventions: Brief Behavioral Activation Treatment for Depression, Cognitive Control Training; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 23
States / cities: Lafayette, California • Lemon Grove, California • Oceanside, California + 20 more

Conditions: Depression, Postpartum
Interventions: NeuroStar Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Neuronetics; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Hartford, Connecticut • Gainesville, Florida • Pensacola, Florida + 5 more

Conditions: Depression
Interventions: Behavioral intervention (iCBT + TeleCoach), Internet-based cognitive behavioral therapy (I-CBT), Treatment as usual / Wait-list control; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 19 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder, Nicotine Dependence
Interventions: bupropion and smoking cessation behavioral intervention; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Chronic Affective Disorders, Cardiovascular Disease Risk
Interventions: Life Goals Collaborative Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depressive Disorder
Interventions: Pramipexole; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers, Depression
Interventions: Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride; Device · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Major Depressive Disorder 1
Interventions: Pharmacogenetic testing; Genetic
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Major Depressive Disorder
Interventions: Intermittent Theta Burst Stimulation (iTBS), Transcranial Alternating Current Stimulation (tACS), Psychotherapy, Sham (Placebo) Transcranial Alternating Current Stimulation (tACS); Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depressive Disorder, Major
Interventions: Testosterone gel, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 23
States / cities: Carlsbad, California • Los Angeles, California • Stanford, California + 20 more

Conditions: Major Depressive Disorder
Interventions: Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training; Other
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder (MDD)
Interventions: SPN-821 2400 mg, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more

Conditions: Depression and Suicide
Interventions: Cognitive Behavioral Therapy CBT, TAU; Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: Ketamine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder, Irritable Bowel Syndrome
Interventions: Ganeden BC30, Placebo (sugar pill), Ganeden BC30, Placebo (sugar pill); Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Burlington, Massachusetts • Westborough, Massachusetts

Conditions: Depressive Disorder, Major
Interventions: Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator; Device
Lead sponsor: Cervel Neurotech, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Atlanta, Georgia • Baltimore, Maryland • Lebanon, New Hampshire + 3 more

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients

Therapist-Guided Smartphone-Delivered CBT for MDD

Reducing the Risk of Developing Major Depression in Adolescents/Young Adults With Minor Depression/Depression Symptoms

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

Effectiveness of a Technology Assisted Behavioral Intervention in Assisting People With Major Depressive Disorder

Treatment of Nicotine Dependence and Acute Depression

Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness

Imaging Dopamine Release in Depression

Neurobiology of Suicide

Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

CARED : A Novel Rapid Treatment Paradigm for Depression

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression

Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD)

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention

Biomarkers of Fast Acting Therapies in Major Depression

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)